Research Article
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
Table 2
Strategy for determining CD-LD ER dose and frequency (N = 90).
| | n (%) |
| Dosing table (survey question 10) | | Not aware | 0 | Helpful to convert | 9 (10) | Not helpful and do not use | 34 (38) | Somewhat useful along with own calculations | 47 (52) |
| Dose conversion strategy (survey question 11) | | Based on the label | 6 (7) | Based on total daily CD-LD IR dose | 44 (49) | Based on individual CD-LD IR dose | 18 (20) | Other | 22 (24) |
| Dose frequency strategy (survey question 14) | | TID and then adjust | 20 (22) | QID and then adjust | 11 (12) | CD-LD ER dose same as CD-LD IR dose | 8 (9) | CD-LD ER dose one less than CD-LD IR dose | 24 (27) | CD-LD ER TID or QID if CD-LD IR QID or 5x per day, respectively | 27 (30) |
|
|
CD-LD = carbidopa-levodopa; IR = immediate-release; ER = extended-release; TID = three times a day; QID = four times a day.
|